View 2-notice timelineLatest notice released 11 Sept 2026
Public SectorUpdate 2 notices
Tate Galleries - Tate Time Machine
Tate Modern's Turbine Hall is one of London's most iconic artistic spaces, where anyone can come in, look around and encounter art. Since it opened in 2000, over 60 million people have experienced the Turbine Hall. We want visitors to feel that the Hall and Tate Modern are a welcoming space, where they can encounter surprising, exciting and accessible digital experiences that connect them to Tate and spark fun and amazement.
We want visitors walking through the Turbine Hall to encounter an easy, direct, playful way of being transported back in time and seeing some iconic Turbine Hall commissions, experiencing 360 / 180-degree recreations of past Turbine Hall commissions through mixed reality.
For those who remember the commissions this would spark a memory and sense of connection to Tate. For those who don't remember a commission, they would be surprised by what they see.
The experience goes beyond passive viewing by including the option of designing your own commission and seeing the Turbine Hall come alive with your own ideas.
Prototyping and Future Contract
This tender is for the design and delivery of the Tate Time Machine prototype. It is the first phase of this opportunity, and we want to be clear from the outset about how the two are connected.
The prototype is not an end in itself. It is what Tate will use to secure funding from our partners for the full rollout of the experience; this funding bid is currently estimated in the region of £150,000. The successful supplier will play a central role in that effort: the quality and credibility of what you build will directly shape whether the funding bid succeeds, and we will look to you to support it by providing material, technical insight and, where helpful, taking part in conversations with prospective funders.
If that funding is secured, Tate will award the full rollout to the awarded tenderers from this process as an option under this contract, without a further competition, subject to satisfactory completion of the prototype phase and agreement of Phase 2 pricing and terms. This is why the competition is evaluated based on the whole project rather than the prototype alone, and why we are asking you about scalability, extensibility and long-term maintenance: we are appointing a partner for the full experience, not a contractor for a single piece of work.
If the bid to our partners is unsuccessful, the contract will conclude at the end of the prototype phase, the option will not be exercised, and no further work will follow. Tate gives no guarantee or commitment that the rollout will proceed, and Tenderers should plan and price the prototype phase on the basis that it may be the entirety of the work awarded.
View 2-notice timelineLatest notice released 11 Sept 2026
Public SectorTender 7 days left 3 notices
Annual Report and Accounts - Creative and Design Agency
The Crown Estate is seeking to appoint a creative agency to support the design, production and delivery of its Annual Report and Accounts together with associated supplementary reporting documents.
The appointed agency will collaborate closely with internal teams to deliver a clear, credible, and well structured Annual Report and Accounts that meets statutory and best practice reporting expectations.
The scope of work includes the Primary Annual Report and Accounts alongside three supplementary documents, the Wales Review, Northern Ireland Review and Sustainability Data Supplement as required.
The contract is for 3 years initially with the option to extend for 2 additional years (1+1).
View 2-notice timelineLatest notice released 23 Sept 2026
Public SectorPlanning
Countermeasures and Preparedness Products
The UK Health Security Agency (UKHSA) intends to establish a Framework Agreement for the provision of Countermeasures and Preparedness products (the “Framework Agreement”). The Framework Agreement will be available for use by UKHSA and potentially other eligible public sector organisations such as the Ministry of Defence (MOD). The Framework Agreement will provide access to a range of pre-approved suppliers and their products.
At this stage, it is intended that the Framework Agreement will comprise multiple lots including, but not limited to:
- Antivirals
- Antibiotics
- Antitoxins
- Antivenoms
- Antidotes
- Vaccines
- Immunoglobulins
- Intravenous Fluids (IV's)
- ICU Medicines
- Radiation Treatments
- Medical Consumables (used in administering the medicines)*
- Combined Needles and Syringes*
*For the purposes of preliminary market engagement, we have included all products in scope of our portfolio. To confirm, recently awarded contracts will continue for their term.
The proposed scope and lotting structure will be explored further during the preliminary market engagement, with the final lotting structure confirmed in the UK 4 Tender Notice for this procurement.
Suppliers will be awarded places on the Framework Agreement based on their ability to meet quality standards and deliver value for money. UKHSA is committed to working with suppliers who support Sustainability and Social Value objectives, and these elements are expected to form part of the award criteria, details of which will be set out in the tender documentation.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyLondonWAC-633145
This UK3 Planned Procurement Notice is issued for information purposes only. The UK Health Security Agency (UKHSA) is not inviting responses to this notice.
UKHSA recently conducted preliminary market engagement in respect of a Hydrogen Peroxide Generator for use in the Biosafety, Air and Water Microbiology Group at Porton Down. For further details please see the Preliminary Market Engagement Notice identifier 2026/S 000-064485 published on 09 July 2026.
Hydrogen Peroxide Generator - Find a Tender
The market engagement stage has now ended and the UKHSA intends to proceed with a below threshold open procedure.
The UKHSA is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as on the global stage. UKHSA ensures the nation can respond quickly and at greater scale to deal with pandemics and future threats. It does this through advocacy, partnerships, world-class science, knowledge and intelligence, and the delivery of specialist public health services. UKHSA is an operationally autonomous executive agency of the United Kingdom Department of Health and Social Care (DHSC).
The UKHSA has a requirement a hydrogen peroxide generator, for the decontamination of interior room surfaces and equipment. The system will support forthcoming research activities within a model (mock) healthcare environment at its Porton Down site.
The UKHSA intends to proceed with an open procedure to procure the equipment and associated services and this notice is to provide notification of the forthcoming invitation to tender.
The specification is currently being prepared however is expected to include a hydrogen peroxide generator which is/has:
• A standalone unit capable of being easily transported and designed to minimise any possible exposure of staff to the sterilant.
• Capable of decontamination of rooms with volumes ranging from 5 to 225 m3.
• Controllable from outside of the room being decontaminated.
• Capable of measuring and recording the environmental conditions in the room (e.g. temperature and humidity).
• Capable of data storage to provide a record of the cycle and parameters obtained.
• A simple closed loop cycle including an aeration step to ensure all vapours are removed by the end of the process.
• Circulation and aeration units as required by the technology.
• An independent hydrogen peroxide monitor for leak detection and final safety check for safe entry to room after cycle completion.
• Capability for users to modify the cycles.
• Availability of hydrogen peroxide consumable for purchase in containers and volumes that can be used with the generator. Hydrogen peroxide consumables must have a shelf life of at least six (6) months from the date of delivery when ordered from the Supplier.
• Capable of monitoring and recording the hydrogen peroxide concentration within the room being decontaminated.
• Suitable for use in healthcare settings in the UK.
• Compliant with BS EN 17272:2020+A1:2025.
The equipment must be supplied inclusive of:
• Delivery to UKHSA premises at Porton Down.
• Commissioning of the equipment.
• Comprehensive training, on the safe use of the equipment and cycle development, to UKHSA nominated staff.
• Technical support for UKHSA staff for the duration of the Contract.
• Routine servicing, in accordance with the regime set out by the original equipment manufacturer (OEM), for a minimum of two (2) years from the date of delivery (or commissioning if later) to UKHSA. Servicing to include all preventative maintenance and replacement of parts where such replacement is set out in OEM’s servicing regime.
• Technical support for the duration of the Contract. To include breakdown labour costs and rapid on-site response where required.
• Manufacturer’s warranty.
This notice is for information only and the information contained herein, including information relating to the nature and scope of the requirement, the estimated value and dates, is indicative only and is neither exhaustive nor binding and the Authority reserves the right, at its absolute discretion, to amend it at the time of issue of any further notices or at any other time.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyLondonWAC-650303
Vaccine Prospectus: National Immunisation Programme and vaccine products
Improving health outcomes through vaccines is a priority for the UK Health Security Agency (UKHSA). We aim to use UKHSA's capabilities across the full vaccine pathway to facilitate innovation and support the development and deployment of safe and effective vaccines, ensure the reliable and timely procurement, storage and distribution of vaccines, and drive increased uptake among the population to reduce the burden of infectious disease.
UKHSA published a Vaccine Prospectus in August 2026, which sets out the work that UKHSA and the wider health family do to sustain and grow the UK's world-leading role in immunisation. It details the scope of our programmes, our policy objectives, how we work with industry, and forthcoming opportunities to work with us.
The publication can be accessed here: https://www.gov.uk/government/publications/vaccine-prospectus-national-immunisation-programme-and-vaccine-products
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-648887
The key dates for this RFI are as follows:
RFI Published: 28 August 2026
RFI Response: 11 September 2026
Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response.
If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.
Description of Scope of Requirements:
The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure.
Background:
The UKHSA Sequencing Laboratories in Bristol, Colindale, Manchester, and Porton Down offer nucleic acid sequencing services to support a variety of public health and clinical functions. These services currently include ongoing pathogen surveillance programmes, clinical metagenomics sequencing, and outbreak detection. As part of the UKHSA Pathogen Genomics Strategy and Pandemic Preparedness Programme, we are looking to maintain and expand the capacity and efficiency of our Genomics services. We therefore wish to explore available liquid handling robotics to support sequencing laboratory processing.
Should you wish to respond to this Request for Information or require more information, please follow the link below:
https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001uBE2zIAG&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-645740
UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Doxycycline 10 pack through this Request for Information (RFI), in accordance with the Procurement Act 2023.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-642442
UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Pralidoxime Chloride through this Request for Information (RFI), in accordance with the Procurement Act 2023.
Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-639502
Provision of immunisations which protect against, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib) and hepatitis B programmes (2028).
Provision of immunisations which protect against, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib) and hepatitis B programmes for supply from 2028. Contract length is still under review but may be required up to a period of 3 years with the option to extend for a period or periods up to an additional 24 months. The opportunity will be split into lots.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-634179
The Crown Estate, as manager of the seabed around England, Wales and Northern Ireland, periodically holds competitive tenders to award seabed rights for the development, construction and operation of offshore wind farms.
In September 2024, The Crown Estate set out its approach to bringing such future tenders to market in its Future of Offshore Wind publication (Future of offshore wind | The Crown Estate). This was published alongside a report setting out our ambition to develop a Marine Delivery Routemap, which is intended to help enable a more holistic approach to be taken in relation to seabed development in the future.
With the announcement in March 2026 of our intention to launch a new leasing round in 2027 (Offshore Wind Leasing Round 6) and building on the approach taken by The Crown Estate in previous leasing rounds, such as Offshore Wind Leasing Rounds 4 and 5, The Crown Estate is committed to engaging with a broad spectrum of market participants and other stakeholders through a series of webinars and questionnaires in 2026 to inform the development of its Leasing Round 6 and future leasing processes.
In this context, The Crown Estate intends to undertake further preliminary market engagement in accordance with the Procurement Act 2023, in relation to the design of Leasing Round 6 and future leasing rounds, through the following activity which is targeted at existing and prospective offshore wind developers and project investors only.
Spatial design Webinar – Thursday 23rd July 2026. This is planned to be a live presentation from The Crown Estate Spatial Design team, sharing the next stage of our spatial design process and some related information. We intend to provide an opportunity for attendees to participate in a live question and answer session. We are considering also offering attendees the opportunity to provide written feedback on the content of the webinar through an online link shared after the event.
Bilateral discussions with developers and investors up until close to the date of the Information Memorandum (IM) being issued for Round 6, which is planned for the first half of 2027. The Crown Estate intends to hold a series of bilateral meetings with offshore wind developers and investors on the developing market proposition for Round 6 from July 2026. As there is no firm date yet for the Information Memorandum, an interim deadline for this engagement has been set for the 28 February 2027.
The intention is that the webinar and bilateral discussions will provide The Crown Estate with further opportunities to gather individual and industry-wide perspectives, thereby ensuring that the evolving needs and priorities of the offshore wind sector as a whole can be taken into account by The Crown Estate when shaping Leasing Round 6 and future leasing opportunities.
This market engagement is intended for existing and prospective offshore wind developers and investors only, i.e. those who have the capacity and interest in bidding in a leasing round, either as a sole bidder or as part of a consortium or other joint venture. If offshore wind project development and investment companies wish to participate in any of these market engagement events, then they should apply by sending an email to [email protected].
The Crown Estate is also willing to have a session with any offshore wind developer or investor to provide an overview of any preliminary market engagement webinars they have missed or have a bilateral discussion. The Crown Estate intends to engage with other relevant stakeholders separately at appropriate times and in an appropriate way.
The Crown Estate is in the process of designing future offshore wind leasing rounds, which these discussions will inform. There is currently no formal date for the launch of Offshore Wind Leasing Round 6. The date set out below (the “Engagement deadline”) refers to the engagement activities which are the subject of this PME Notice, rather than any contract notice for a leasing process.
For the avoidance of doubt, this notice is not a call for competition, and any subsequent procurement process will be commenced with one or more Tender Notice(s) in accordance with the Procurement Act 2023. The preliminary market engagement exercise is not an inducement to make any investment decision(s).
For further information on The Crown Estate’s involvement in offshore wind, please visit https://www.thecrownestate.co.uk/our-business/marine/offshore-wind.
St James's Market Phase 2 - Demolition and Enabling Works
The Crown Estate is seeking to appoint a contractor to deliver the demolition and enabling works for St James's Market Phase 2 (SJM2). The works include demolition of existing buildings and foundations, asbestos removal, underpinning works, infilling of pavement vaults, temporary works to support retained structures where required, site-wide clearance and excavation, and installation of the piling mat. The procurement is being conducted through a Competitive Flexible Procedure and will be delivered in two stages comprising a Conditions of Participation (COP) and Procurement Specific Questionnaire (PSQ), followed by an Invitation to Tender (ITT) for suppliers meeting the required standards.
The employer under the contract will be St James's Market Development (No. 2) Limited. This entity is a wholly owned subsidiary of the Crown Estate Commissioners. Further information is provided to tenderers within the procurement briefing pack.
UK Health Security Campus, Harlow – Major science, headquarters and campus infrastructure works
The UK Health Security Agency (UKHSA) is preparing to engage the market on a major construction opportunity in Harlow, Essex. The opportunity sits within the UK Health Security Campus Programme: a once-in-a-generation investment to create a modern, purpose-built national health security and biosecurity campus.
The new campus will bring together UKHSA’s specialist scientific facilities from Porton Down and Colindale and its London headquarters functions onto a single integrated site in Harlow. The campus is intended to provide modern laboratories, office accommodation and supporting infrastructure to strengthen the UK’s ability to detect, assess and respond to serious public health and biosecurity threats.
This Preliminary Market Engagement Notice relates to the procurement of a Tier 1 construction contractor for the design and build of the campus facilities and infrastructure outside the separately managed high-containment laboratory building. In practical terms, the potential requirement is expected to include a new science and headquarters building, medium-containment laboratory capability, office accommodation, energy centre, logistics and support facilities, arrivals and education facilities, external works, utilities, site infrastructure and associated campus-wide integration.
The separately managed high-containment laboratory building, which will contain the most specialist Containment Level 4 capability, will be delivered through a separate agreement and is not the focus of this engagement activity.
UKHSA is using this engagement to test and develop the core commercial considerations, such as; whether the remaining campus works should ideally be delivered through a single Tier 1 design and build model, or whether alternative delivery models would improve deliverability, competition and value for money.
The potential requirement would include:
• a new science and headquarters building providing modern laboratory, technical and office accommodation for around 2400 FTE ;
• containment Level 2 and Containment Level 3 laboratory areas and associated technical environments;
• office space and shared facilities to support the relocation and co-location of UKHSA staff;
• logistics, warehousing, support and campus operations facilities;
• arrivals, reception, security, education, training and outreach facilities;
• site-wide infrastructure, a dedicated energy centre, utilities, external works, access, parking and enabling works;
• coordination with the separately managed high-containment laboratory project and other programme workstreams;
• construction logistics, phasing, mobilisation, commissioning support and handover planning;
• health, safety, environmental, quality, security and regulatory coordination requirements;
• sustainability, carbon reduction, energy efficiency, materials reuse and social value outcomes.
The opportunity is part of a wider programme targeting full campus operational readiness by 2038. Key programme activities include advanced works and main construction during the late 2020s and early 2030s, followed by transition, commissioning, validation and relocation activity through the mid-to-late 2030s. Further detail on the programme timings will be available via the engagement process and may be subject to change as work progresses.
The final scope, procurement route, contract model, packaging strategy, value and timetable remain subject to approval and are likely to change following market engagement and further project development. The estimated costs within this notice represent the anticipated cost of the construction work associated with this opportunity. Through the market engagement process, the Agency will be able to provide additional detail on expected value vs potential value.
This notice is for preliminary market engagement only. It is not a call for competition and does not commit UKHSA to commence a procurement or award a contract.
Related professional services opportunity
UKHSA is also progressing related professional services procurement activity to support the wider UK Health Security Campus Programme. This activity is expected to support the development, assurance, design, commercial, technical and delivery readiness of the programme.
The professional services opportunity and this preliminary market engagement for the proposed Harlow science, headquarters and supporting campus infrastructure works are separate but related elements of the wider programme. Suppliers should note that the professional services activity is intended to support the development and delivery of the programme, while this notice relates to market engagement with organisations interested in the future construction delivery opportunity.
UKHSA is referencing the related professional services activity in this notice to provide market context and to help suppliers understand the broader programme landscape. Interested suppliers should review any separately published notices for the professional services opportunity where relevant.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-623805
The Crown Estate- Managing Agents Asset Management
The Crown Estate (TCE) is undertaking a strategic procurement to appoint Managing Agents to deliver a broad range of asset, contract, compliance, and customer management services across its diverse UK portfolio, comprising coastal, marine, minerals, and infrastructure assets.
This procurement is segmented into multiple lots to ensure the specific geographic and sectoral needs of each portfolio are met, with a focus on securing specialist expertise, operational resilience, and continuous service improvement.
The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement.
The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI.
The UK Health Security Agency’s (UKHSA) key objectives for this RFI are:
understand the ability of the marketplace to fulfil its requirements;
refine the scope of the requirements to best align to the marketplace; and
inform the Authority’s chosen route to market to best enable competition
The key dates for this RFI are as follows:
RFI Published: 30th June 2026
RFI Response: 14th July 2026
Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response.
If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.
Description of Scope of Requirements:
The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure.
Background:
UKHSA is seeking to engage with the market to better understand supplier capability for the provision of lyophilisation (freeze-drying) services for X-ray irradiated pathogens to provide greater resilience and flexibility across use cases as part of UKHSA’s Pandemic Preparedness strategy.
UKHSA requires support in developing optimal formulations and lyophilisation processes to ensure that irradiated, inactivated pathogens can be safely stored, handled, and distributed for diagnostic use and pandemic preparedness. Lyophilisation is required to enhance the long-term stability and usability of these materials, supporting strategic resilience and response capabilities.
Requirements:
We need the supplier to have:
• Ability to handle irradiated, inactive viral and bacterial material in liquid medium
• Ability to develop and optimise lyophilisation protocols including assessment of different stabilisation matrices
• Appropriate quality system in place (at least ISO 9001) to ensure consistency and traceability
• Provide product quality control (QC) testing of final product, including thermal stability and absence of contaminants.
• Overall aim is to lyophilise up to 20 pathogens over the next 4 years
o Estimated vial volume for lyophilisation is 0.3mL – 2mL
o Estimated batch size for lyophilisation is 6 – 100mL
o Estimated number of batches per year is 5
Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001jEyqdIAC&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-617995
UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Botulinum Antitoxin Heptavalent (HBAT) through this Request for Information (RFI), in accordance with the Procurement Act 2023.
The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-616848
UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Prussian Blue through this Request for Information (RFI), in accordance with the Procurement Act 2023.
The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyWAC-616849